Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Fr | Sanofi/Sobi's efanesoctocog alfa recommended by CHMP to treat haemophilia A | 7 | PMLiVE | ||
26.04. | Sobi Reports Positive CHMP Opinion For Efanesoctocog Alfa | 4 | RTTNews | ||
26.04. | Swedish Orphan Biovitrum AB: Sobi® receives positive CHMP opinion recommending approval of efanesoctocog alfa for once-weekly treatment of haemophilia A | 184 | PR Newswire | STOCKHOLM, April 26, 2024 /PRNewswire/ -- Sobi® today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion recommending... ► Artikel lesen | |
26.04. | Swedish Orphan Biovitrum AB: Sobi establishes MTN programme with a framework amount of SEK 10 billion, publishes a base prospectus | 215 | PR Newswire | STOCKHOLM, April 26, 2024 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) has established a medium term note programme with a framework amount of SEK 10 billion or the equivalent... ► Artikel lesen | |
25.04. | Swedish Orphan Biovitrum AB reports Q1 results | 5 | Seeking Alpha | ||
25.04. | Swedish Orphan Biovitrum AB: Sobi Q1 2024 report: Strong sales reflecting the strength of the portfolio | 277 | PR Newswire | STOCKHOLM, April 25, 2024 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the first quarter 2024
First Quarter 2024
Total revenue increased... ► Artikel lesen | |
15.04. | Swedish Orphan Biovitrum AB: Invitation: Sobi's Q1 2024 report | 627 | PR Newswire | Sobi plans to publish its report for the first quarter of 2024 on 25 April 2024 at 08:00 CEST.
STOCKHOLM, April 15, 2024 /PRNewswire/ -- Investors, analysts and media are invited to... ► Artikel lesen | |
04.04. | Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ) | 390 | PR Newswire | STOCKHOLM, April 4, 2024 /PRNewswire/ -- The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Annual General Meeting (the "Meeting")... ► Artikel lesen | |
02.04. | Swedish Orphan Biovitrum AB: Sobi publishes Annual and sustainability report for 2023 | 386 | PR Newswire | STOCKHOLM, April 2, 2024 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) today published its Annual and sustainability report for 2023. Inspired by caring and powered by science... ► Artikel lesen | |
27.03. | Sobi shares positive phase 3 results for Doptelet in paediatric patients with rare blood disorder ITP | 2 | PMLiVE | ||
29.02. | Profit inflection ahead - Berenberg starts Sobi with 'buy' | 12 | Reuters | ||
22.02. | Bechtle, Schneider Electric, Sobi | 26 | Reuters | ||
13.02. | SWEDISH ORPHAN BIOVITRUM AB: Sobi and Handok establish joint venture for rare disease business in South Korea | 5 | Cision News | ||
12.02. | Orexo AB Advances Exploratory Feasibility Study with Sobi | 1 | Contract Pharma | ||
12.02. | Orexo and Sobi agree to advance feasibility study with AmorphOX | 282 | PR Newswire | Orexo and Sobi advance collaboration after successful exploratory feasibility study with the company's world-class drug delivery platform, AmorphOX®The feasibility study confirmed that the... ► Artikel lesen | |
08.02. | Swedish Orphan Biovitrum AB Non-GAAP EPS of SEK3.21, revenue of SEK6.84B | 5 | Seeking Alpha | ||
08.02. | Swedish Orphan Biovitrum AB: Sobi publishes Q4 2023 report: Strong revenue performance and growth into 2024 | 397 | PR Newswire | STOCKHOLM, Feb. 8, 2024 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the fourth quarter 2023.
Fourth Quarter 2023
Total revenue increased... ► Artikel lesen | |
08.02. | Sobi falls on Q4 profit, 2024 outlook below estimates as costs weigh | 8 | Reuters | ||
02.02. | Sobi receives NICE recommendation for Zynlonta in two non-Hodgkin lymphomas | 4 | PMLiVE | ||
02.02. | Close Brothers Group, IMCD, Swedish Orphan Biovitrum | 7 | Reuters |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 39,940 | +0,90 % | Qiagen bekräftigt Prognose für 2024 - erste Expertenstimmen | Das Biotech-Unternehmen Qiagen meldet für das erste Quartal 2024 einen Umsatzrückgang von 485,4 Millionen Dollar auf 458,8 Millionen Dollar. Das Betriebsergebnis ist leicht gefallen und liegt bei 94... ► Artikel lesen | |
EVOTEC | 9,760 | -1,36 % | Delivery Hero, pbb, Evotec, K+S, TAG Immobilien, Varta und Co. - Aktien-Positionen der Shortseller | Wer Aktien leer verkauft, das sogenannte Shortselling, muss Transparenzpflichten erfüllen. Wir werfen einen Blick auf aktuelle Shortseller-Meldungen. Geregelt sind diese in der EU-Leerverkaufsverordnung... ► Artikel lesen | |
SPRINGWORKS THERAPEUTICS | 45,110 | +4,06 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates | - Achieved $21.0 million in OGSIVEO® (nirogacestat) net product revenue in the first quarter - - Received validation from the EMA for MAA of nirogacestat for the treatment of adults with desmoid tumors... ► Artikel lesen | |
KYMERA THERAPEUTICS | 37,400 | +3,03 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update | KT-474/SAR444656 (IRAK4) Phase 2 clinical trials ongoing in HS and AD with data expected in the first half of 2025 KT-621 (STAT6) expected to start Phase 1 in the second half of 2024 and KT-294 (TYK2)... ► Artikel lesen | |
ARCUTIS BIOTHERAPEUTICS | 8,000 | -6,98 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | WESTLAKE VILLAGE, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in... ► Artikel lesen | |
DYNE THERAPEUTICS | 26,080 | +0,31 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights | - Additional Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Anticipated in the Second Half of 2024 - WALTHAM, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Dyne... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 8,840 | +0,57 % | (RXRX) - Analyzing Recursion Pharmaceuticals' Short Interest | ||
NUVALENT | 70,35 | -2,95 % | Nuvalent, Inc.: Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024 | Preclinical data continue to support NVL-330's broad activity against HER2 oncogenic alterations, selectivity over wild-type EGFR, and differentiated brain-penetrant profile
Zidesamtinib shown to... ► Artikel lesen | |
CG ONCOLOGY | 36,270 | -8,18 % | CG Oncology Inc.: Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer | - Phase 3 BOND-003 study results showed sustained, durable complete responses over 12 months with novel investigational oncolytic immunotherapy - - Company will hold an investor conference call today... ► Artikel lesen | |
JANUX THERAPEUTICS | 64,78 | +3,76 % | Janux Therapeutics jumps as much as 28% on heels of Deciphera buyout deal | ||
ANNEXON | 4,880 | +4,72 % | Annexon (ANNX) to Report Q1 Earnings: What's in the Cards? | ||
SANA BIOTECHNOLOGY | 10,440 | +6,75 % | Sana Biotechnology, Inc: Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates | Goal to treat 40-60 patients in 2024 in four trials across seven indications in oncology, B-cell mediated autoimmune diseases, and type 1 diabetes Early SC291 data from ongoing ARDENT trial in relapsed/refractory... ► Artikel lesen | |
CABALETTA BIO | 12,390 | -1,67 % | Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update | - First patient dosed with CABA-201 in the RESET (REstoring SElf-Tolerance) clinical trial program - - Initial clinical data from each of the first patients in the RESET-Myositis and RESET-SLE trials... ► Artikel lesen | |
ARCTURUS THERAPEUTICS | 27,270 | +2,83 % | Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress | SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 26,450 | +3,40 % | Navigating 7 Analyst Ratings For Avidity Biosciences |